Welcome to our dedicated page for AbbVie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. executive Demetris D. Crum, EVP and Chief HR Officer, reported a tax-related share disposition. On February 27, 2026, Crum disposed of 1,594 shares of AbbVie common stock at $232.08 per share to satisfy tax withholding obligations, a non‑open‑market transaction coded as a tax‑withholding disposition. After this event, Crum directly owned 7,914 AbbVie shares.
AbbVie Inc. completed an underwritten public offering of multiple series of senior unsecured notes. The company issued senior floating rate notes due 2028 with an aggregate principal amount of $750,000,000, along with several series of fixed-rate senior notes maturing between 2028 and 2066.
The fixed-rate series include $1,500,000,000 of 3.775% notes due 2028, $1,250,000,000 of 4.125% notes due 2031, $1,250,000,000 of 4.400% notes due 2033, $1,500,000,000 of 4.750% notes due 2036, $1,250,000,000 of 5.550% notes due 2056, and $500,000,000 of 5.650% notes due 2066. All notes rank equally with AbbVie’s other unsecured, unsubordinated obligations.
The notes were issued under an existing shelf registration and an indenture that includes customary covenants, such as limits on certain liens and restrictions on mergers or transfers of substantially all assets. AbbVie has various optional redemption rights, including make-whole redemptions and par calls after specified dates for each longer-dated series.
AbbVie Inc. executive Roopal Thakkar reported a tax-related share disposition. On February 27, 2026, 8,037 shares of AbbVie common stock were disposed of at $232.08 per share to cover tax obligations, leaving 52,376 directly held shares. The filing also reports 2,998 shares held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings program as of February 20, 2026, including dividend reinvestment shares that were previously omitted from an earlier Form 3.
AbbVie Inc. director and CEO Michael Robert A. reported a Form 4 transaction involving a tax-related share disposition. On February 27, 2026, he had 36,523 shares of common stock disposed of at $232.08 per share to satisfy tax obligations. After this tax-withholding disposition, he directly owned 178,737 shares of AbbVie common stock.
AbbVie Inc. executive vice president and chief commercial officer Jeffrey Ryan Stewart reported a tax-withholding disposition of 23,812 shares of common stock at $232.08 per share on February 27, 2026. After this transaction, he directly owned 83,171 shares. An additional 1,338 shares are held indirectly by his spouse in a trust, and he disclaims beneficial ownership of those securities.
AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported several stock transactions. On February 27, 2026, he disposed of 14,850 common shares at $232.08 per share to cover tax obligations. On March 2, 2026, he conducted open-market sales totaling 18,668 common shares at weighted average prices between about $233 and $235.36. Following these sales, his directly owned common stock holdings were reported in the filing at reduced levels after each transaction.
AbbVie Inc. executive vice president and chief financial officer Scott T. Reents reported a tax-related share disposition under a compensation plan. On February 27, 2026, 21,638 shares of AbbVie common stock were disposed of to cover tax withholding obligations. After this transaction, he directly owned 38,777 AbbVie shares.
AbbVie Inc. executive Azita Saleki‑Gerhardt reported a tax-related share disposition. On February 27, 2026, 16,309 shares of AbbVie common stock were disposed of at $232.08 per share to satisfy tax obligations through share withholding, a non‑open‑market transaction. Following this, she directly held 197,794 AbbVie shares.
In addition, 2,706 AbbVie shares were held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings Program as of February 20, 2026, including dividend reinvestments. A further 3,873 shares were held by her spouse, for which the reporting person disclaims beneficial ownership.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported a tax-related share disposition. On February 27, 2026, he transferred 2,692 shares of AbbVie common stock at $232.08 per share to cover tax obligations, described as a payment of tax liability by delivering securities.
After this transaction, he directly owned 7,884 shares of AbbVie common stock. He also had an indirect holding of 543 shares through a profit sharing trust, with a footnote noting this balance in an AbbVie savings program as of February 20, 2026, including shares acquired via a dividend reinvestment feature.
AbbVie Inc. executive Nicholas Donoghoe reported a tax-related share disposition under a compensation plan. On February 27, 2026, he used 12,874 shares of common stock, valued at $232.08 per share, to cover tax withholding. After this transaction, he directly held 74,430 shares of AbbVie common stock.